Clinical Roundup New AI model can prevent unnecessary prostate removals September 13, 2024Vol.50 No.34
Clinical Roundup T-DXd shows promising results in treating HER2+ metastatic colorectal cancer September 13, 2024Vol.50 No.34
Clinical Roundup Immunological features predict treatment response for advanced solid tumors September 13, 2024Vol.50 No.34
Drugs & Targets FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy September 13, 2024Vol.50 No.34
Drugs & Targets FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas September 13, 2024Vol.50 No.34
Drugs & Targets FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee September 13, 2024Vol.50 No.34
Drugs & Targets Astera Cancer Care, Knowtex collaborate to develop AI automation in oncology September 13, 2024Vol.50 No.34
Conversation with The Cancer Letter Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays September 06, 2024Vol.50 No.33By Paul Goldberg
NCI As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5BRathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” September 06, 2024Vol.50 No.33By Jacquelyn Cobb
Trials & Tribulations Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations? September 06, 2024Vol.50 No.33By Rebecca Sutphen, Sue Friedman and Jon Florin
